Science

FynomAbs

Bi- and trispecific FynomAbs are generated by genetically fusing human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes of action and enhanced efficacy for the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.
Read More >>

Fynomers

Fynomers are small binding proteins derived from the human Fyn SH3 domain. Covagen’s highly diverse library includes 80 billion distinct Fynomers that can bind with high affinity to virtually any antigen of interest. Genetic fusion of Fynomers to an antibody of choice allows the straightforward production of multispecific FynomAbs.
Read More >>